指南与共识肝病

ACG临床指南:酒精相关性肝病

ACG Clinical Guideline: Alcohol-Associated Liver Disease.
指南 / 共识 · Am J Gastroenterol · 2023-09-01

酒精相关性肝病(ALD)是全球晚期肝病和肝移植的常见病因,近十年有害饮酒增加使疾病负担快速上升。本指南由美国胃肠病学会实践参数委员会制定,采用GRADE系统评估证据等级和推荐强度,涵盖ALD谱系、酒精相关性肝炎(AH)的严重度分层与治疗、酒精使用障碍(AUD)管理及肝移植选择。

要点

  • 终末期肝病模型评分是分层AH严重度最准确的评分,>20分定义为重度。
  • 皮质类固醇是目前唯一对重度AH有确切疗效的治疗,1个月生存获益见于50%-60%的患者。
  • 肝移植应考虑用于对内科治疗无反应且移植后复饮风险低的特定AH患者。

核心结论

  • 酒精相关性肝病是全球晚期肝病和肝移植的常见病因,随着有害饮酒增加,相关医疗负担快速上升。
  • 戒酒是ALD长期结局的关键决定因素,但合并酒精使用障碍(AUD)的ALD患者难以实现戒酒。
  • 肝移植是晚期肝硬化患者的确定性治疗选择,应考虑用于对内科治疗无反应且移植后复饮风险低的特定AH患者。

研究设计与样本

  • 本指南由美国胃肠病学会实践参数委员会制定。
  • 采用推荐分级的评估、制定与评价(GRADE)系统评估证据等级和推荐强度。
  • 原文未报告系统检索范围。

主要发现

  • ALD谱系从早期无症状肝损伤到伴失代偿和门静脉高压的晚期疾病。
  • 与其他病因肝病患者相比,ALD患者进展更快且更常以晚期阶段就诊。
  • 重度AH表现为黄疸快速出现或加重,严重形式可发生慢加急性肝衰竭,1个月死亡风险为20%-50%。
  • 终末期肝病模型评分是分层AH严重度最准确的评分,>20分定义为重度疾病。
  • 皮质类固醇是目前唯一对重度AH有确切疗效的治疗,在50%-60%的患者中提供1个月生存获益。

关键数值与推荐

  • 终末期肝病模型评分>20分定义为重度AH。
  • 皮质类固醇在50%-60%的重度AH患者中提供1个月生存获益。
  • 肝移植应考虑用于对内科治疗无反应且移植后复饮风险低的特定AH患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alcohol-associated liver disease (ALD) is the most common cause of advanced hepatic disease and frequent indication for liver transplantation worldwide. With harmful alcohol use as the primary risk factor, increasing alcohol use over the past decade has resulted in rapid growth of the ALD-related healthcare burden. The spectrum of ALD ranges from early asymptomatic liver injury to advanced disease with decompensation and portal hypertension. Compared with those with other etiologies of liver disease, patients with ALD progress faster and more often present at an advanced stage. A unique phenotype of advanced disease is alcohol-associated hepatitis (AH) presenting with rapid onset or worsening of jaundice, and acute on chronic liver failure in severe forms conveying a 1-month mortality risk of 20%-50%. The model for end stage disease score is the most accurate score to stratify AH severity (>20 defined as severe disease). Corticosteroids are currently the only available therapeutic with proven efficacy for patients with severe AH, providing survival benefit at 1 month in 50%-60% of patients. Abstinence of alcohol use, a crucial determinant of long-term outcomes, is challenging to achieve in ALD patients with concurrent alcohol use disorder (AUD). As patients with ALD are rarely treated for AUD, strategies are needed to overcome barriers to AUD treatment in patients with ALD and to promote a multidisciplinary integrated care model with hepatology, addiction medicine providers, and social workers to comprehensively manage the dual pathologies of liver disease and of AUD. Liver transplantation, a definitive treatment option in patients with advanced cirrhosis, should be considered in selected patients with AH, who are unresponsive to medical therapy and have a low risk of relapse to posttransplant alcohol use. Level of evidence and strength of recommendations were evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations system. This guideline was developed under the American College of Gastroenterology Practice Parameters Committee.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Jophlin LL, Singal AK, Bataller R, et al. ACG Clinical Guideline: Alcohol-Associated Liver Disease. Am J Gastroenterol. 2023. PMID: 38174913. doi:10.14309/ajg.0000000000002572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。